ArticleCancer letters2013
2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.
Article in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Role of Serum Stability and Lipoprotein Interactions in Lipid Structure-Tumor Accumulation Relationship.ACS nano · 2025Article
- Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug.International journal of nanomedicine · 2024Article
- Solid Lipid Particles for Lung Metastasis Treatment.Pharmaceutics · 2021Article
- Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- In vivo Serum Enabled Production of Ultrafine Nanotherapeutics for Cancer Treatment.Materials today (Kidlington, England) · 2020Article
- The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: anRSC advances · 2018Article
- Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Nanomedicine (London, England) · 2017Review
- Lipid-Drug Conjugate for Enhancing Drug Delivery.Molecular pharmaceutics · 2017Review
- Rapid microwave-assisted synthesis of sub-30nm lipid nanoparticles.Journal of colloid and interface science · 2017Article
- Nanoparticles for imaging and treatment of metastatic breast cancer.Expert opinion on drug delivery · 2017Review
- Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.Journal of visualized experiments : JoVE · 2016Article
- Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2014Article
- Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.Nano letters · 2014Article
- Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.International journal of nanomedicine · 2014Article
- Nanodrug delivery in reversing multidrug resistance in cancer cells.Frontiers in pharmacology · 2014Review
- 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.International journal of nanomedicine · 2014Article
- Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Nano today · 2013Article
- Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Journal of nanomedicine & nanotechnology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The aim of these studies was to develop a novel 2'-behenoyl-paclitaxel (C22-PX) conjugate nanoparticle (NP) formulation for the treatment of metastatic breast cancer. A lipophilic paclitaxel derivative C22-PX was synthesized and incorporated into lipid-based NPs. Free C22-PX and its NP formulation were evaluated in a series of in vitro and in vivo studies. The results demonstrated that C22-PX NPs were much better tolerated and had significantly higher plasma and tumor AUCs compared to Taxol at the maximum tolerated dose (MTD) in a subcutaneous 4T1 mouse mammary carcinoma model. These benefits resulted in significantly improved antitumor efficacy with the NP-based formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.